Efficacy of Furosap, a novel Trigonella foenum‐graecum seed extract, in Enhancing Healthy Testosterone Level and Improving Sperm Profile in Male Volunteers

Abstract

Furosap, an innovative 20% protodioscin‐enriched extract derived from Trigonella foenum‐graecum seeds, was developed in our laboratory, which effectively increased testosterone levels, sperm profile, mental alertness, mood and libido in male volunteers. This one‐arm, open‐labelled study was conducted in 50 male volunteers (age: 35 to 65 years) over a period of 12 weeks to determine the efficacy of Furosap (500 mg/day/subject). The present study examined the testosterone levels, sperm profile, sperm morphology, libido and erectile dysfunction, mood and mental alertness and broad spectrum safety parameters. Free testosterone levels were improved up to 46% in 90% of the study population. 85.4% of the study population showed improvements in sperm counts. Sperm morphology improved in 14.6% of volunteers. Majority of the subjects enrolled in the study demonstrated improvements in mental alertness and mood. Furthermore, libido was significantly improved. Extensive safety parameter evaluation including extensive blood chemistry data exhibited no significant changes in serum lipid function, cholesterol, triglyceride, HDL and LDL levels, hemogram (CBC), hepatotoxicity and nephrotoxicity. Overall, the results demonstrate that Furosap, enriched in 20% protodioscin, is safe and effective in attenuating testosterone levels, sperm profile, mental alertness and overall performance in human subjects.Support or Funding InformationCepham Inc, Piscataway, NJ, USA